CDSCO Medical Device Registration in India: Engagement Case Studies from Regional Partner Practices (2026)

Quick answer

What do CDSCO medical device registration engagement case studies from regional partner practices show in 2026?

Five confidential field reports from partner practices in the Indian market illustrate machinery manufacturers from EU or US frameworks routinely fail to anticipate: the collision between CDSCO market authorisation and NPPA statutory price control, the Subject Expert Committee (SEC) route for devices without an Indian predicate, the importer paradox of distributor-held Form MD-15 licences, the absence of a dedicated SaMD software rule under the Medical Devices Rules, 2017, and multi-authority approvals (AERB, BIS, Legal Metrology, wireless) for radiation-emitting and measuring devices. Across cases, binding constraints were often price ceilings, population representativeness, SEC/clinical timelines, counterparty leverage, and non-CDSCO approvals — not device safety.

Keywords: CDSCO registration case study, Form MD-14 MD-15 import licence, Device Master File Plant Master File, Sugam portal CDSCO, importer paradox India, Authorised Indian Representative, NPPA price capping medical devices, trade margin rationalisation, Investigational Medical Device India, Subject Expert Committee CDSCO, Medical Devices Rules 2017, SaMD India classification, AI algorithm change control India, AERB type approval medical device, Materiovigilance Programme of India, India medical device regulatory affairs

1. Introduction

The five engagement reports below were contributed by partner practices operating in the Indian regulatory market. They span five manufacturer home countries, four device risk classes, and the principal pathways available under the Medical Devices Rules, 2017 (MD Rules 2017) as amended.

They have been selected to illustrate machinery that is specific to India and that manufacturers accustomed to EU or US frameworks routinely fail to anticipate: the collision between market authorisation and statutory price control, the Subject Expert Committee route for devices without an Indian predicate, the structural consequences of distributor-held import licences, the absence of a dedicated software rule under MD Rules 2017, and the multi-authority approvals required for radiation-emitting and measuring devices.

Manufacturer identities and partner practice names are withheld under engagement confidentiality. Product descriptions have been generalised where necessary to prevent identification.

2. Case Study 1 — Switzerland: Class C Knee Implant System and the Price Control Collision

2.1 Client Profile

2.2 Project Scope and Duration

Scope covered classification confirmation, Authorised Indian Representative appointment, Device Master File and Plant Master File compilation, Form MD-14 submission and prosecution, labelling compliance, and — added at month 11 — price control impact assessment and commercial restructuring.

Duration: 19 months to Form MD-15 issuance. The engagement was extended by a further 7 months to address the pricing consequence, which the manufacturer had not identified as a regulatory-adjacent risk at initiation.

2.3 Product Characteristics

2.4 The Registration Process and Regulatory Strategy

The technical pathway was conventional. As a notified Class C device imported by a foreign manufacturer, registration proceeded via Form MD-14 application to the Central Licensing Authority through the CDSCO online portal, seeking an import licence on Form MD-15. One MD-15 is issued per manufacturing site and enumerates the devices manufactured there, which made site-level portfolio planning a threshold decision: the manufacturer produced components at two sites, and consolidating the submission around a single site for initial entry reduced dossier volume materially at the cost of deferring one cementless variant.

The dossier comprised a Device Master File and a Plant Master File, with the DMF resting substantially on the EU MDR technical documentation and the PMF on the ISO 13485 certificate and site quality documentation. Reference country status was straightforward — Switzerland is not itself a listed reference country under the relevant schedule, but the device held EU MDR certification and US 510(k) clearance, either of which satisfies the requirement.

The strategic decision that shaped the engagement was the treatment of the existing dossier. The manufacturer's initial instruction was to submit the EU MDR technical file substantially as-is, on the reasoning that a Class III EU dossier necessarily exceeds a Class C Indian requirement. The practice declined this approach and conducted a structured gap analysis against MD Rules 2017 Schedule requirements instead.

That decision proved material. The gap analysis identified eleven items present in the Indian requirement set that the EU dossier did not address in the form CDSCO expects — among them the Essential Principles checklist mapped to MD Rules 2017 rather than to MDR Annex I, shelf-life and stability data presented against Indian climatic zone conditions, and a specific format for the undertaking regarding regulatory status in the country of origin. Submitting the EU file unmodified would, in the practice's assessment, have generated a query round costing three to four months in the first-in-first-out queue.

2.5 Health Authority Interaction

CDSCO correspondence across the review produced two query rounds totalling 23 observations.

The first round, issued at month 7, was predominantly administrative and concerned dossier completeness: notarisation and apostille of the Free Sale Certificate, consistency between the device nomenclature in the application and on the CE certificate, and the format of the Authorised Indian Representative undertaking. Nineteen of the 23 observations fell in this round and were closed within six weeks.

The second round, at month 13, was substantive. The reviewer requested justification of the shelf-life claim for the polyethylene insert under Indian storage and transport conditions, noting that the manufacturer's stability data had been generated at ICH Zone II conditions while India falls within Zone IVB. The reviewer also queried the absence of Indian clinical data and requested justification for reliance on non-Indian clinical evidence.

The clinical query was resolved through a justification rather than data generation. The practice's submission argued that total knee arthroplasty is a well-established technology with extensive registry evidence, that the device's design lineage was documented, and that no ethnicity-specific safety or performance concern had been identified in the literature for the implant class. CDSCO accepted this. The practice's assessment is that this outcome is reliably available for well-established device categories and reliably unavailable for novel mechanisms, and that the distinction is worth establishing before the dossier is built.

National Pharmaceutical Pricing Authority interaction was the consequential element and did not involve CDSCO at all. Knee implant systems fall within the scope of statutory price control, with ceiling prices notified by category and periodically revised. The manufacturer's Indian pricing model had been built on a landed-cost-plus basis derived from its European price positioning and did not survive contact with the notified ceiling for its implant category.

2.6 Pitfalls and Solutions

Pitfall: the gap analysis trap. The manufacturer's assumption that a higher-class EU dossier subsumes a lower-class Indian requirement is common and incorrect. The requirement sets overlap substantially but not completely, and the non-overlapping items are not a function of risk class.

Solution. A structured item-by-item gap analysis against MD Rules 2017 before dossier assembly, treating the EU file as a source of content rather than as a submission. The practice's standing position is that dossier reuse from USFDA or EU submissions should always be preceded by gap analysis, and that the cost of the analysis is recovered in avoided query rounds on the first submission.

Pitfall: stability data generated for the wrong climatic zone.

Solution. Accelerated and real-time stability studies were initiated at Zone IVB conditions for the polyethylene component. Because real-time data could not be generated within the review timeline, the manufacturer submitted accelerated data with a commitment to provide real-time data at defined intervals post-approval, which CDSCO accepted. The practice notes that Zone IVB stability is among the most frequently missed requirements for manufacturers entering India from temperate markets, and that initiating stability studies at project start — rather than in response to a query — removes it from the critical path entirely.

Pitfall: price control not identified as a regulatory-adjacent risk. The most commercially significant failure in the engagement.

Solution. A pricing impact assessment was conducted at month 11, once the ceiling category applicable to the device was confirmed. Three responses were modelled: exit, entry at ceiling with a restructured cost base, and entry with a reconfigured product specification positioned in a different ceiling category. The manufacturer selected entry at ceiling with a restructured supply chain, substituting air freight for sea freight on a consolidated schedule and renegotiating distributor margin within the trade margin framework. Gross margin on the line fell from 61% in European markets to 22% in India, which the manufacturer accepted on volume grounds.

The practice's assessment is that price control should be modelled before the registration decision, not after the licence is granted. Registration cost is substantially sunk by the time a ceiling price becomes commercially visible, and a manufacturer that discovers the ceiling after approval has lost the option to decline entry.

3. Case Study 2 — United States: AI Retinal Screening Software and the Absence of a Software Rule

3.1 Client Profile

3.2 Project Scope and Duration

Scope covered classification determination, Authorised Indian Representative appointment, dossier compilation, Form MD-14 prosecution, algorithm change control framework design, and remediation of the pre-registration deployment exposure.

Duration: 22 months. The extended timeline was driven principally by classification ambiguity, which consumed the first five months before dossier work could begin meaningfully.

3.3 Product Characteristics

3.4 The Registration Process and Regulatory Strategy

The defining feature of this engagement is structural: MD Rules 2017 contains no rule dedicated to software as a medical device. Software falls within the definition of a medical device where it meets the intended-purpose criteria, and classification proceeds by applying the general risk-based classification framework to the software's intended use. There is no analogue to EU MDR Annex VIII Rule 11 that provides a decision structure specific to software.

The consequence is that classification is a matter of construction and argument rather than rule application, and the manufacturer's EU Class IIa determination carried no automatic weight. The practice's analysis considered three positions. Class B was arguable on the basis that the software performs screening triage rather than diagnosis and that a clinician retains decision authority. Class C was arguable on the basis that a false-negative referral output could result in delayed treatment of sight-threatening disease. Class D was not seriously arguable.

The practice recommended proceeding on a Class C basis and — critically — seeking confirmation rather than asserting it. A classification clarification request was submitted before the Form MD-14 application, which cost approximately four months at the front of the project and removed the risk of a mid-review reclassification that would have invalidated the fee paid and the dossier structure.

The second strategic element was the algorithm change control framework. The manufacturer operated a continuous model improvement pipeline, retraining on accumulated data at roughly quarterly intervals. MD Rules 2017 provides for post-approval changes through endorsement of the existing licence, but the framework was not designed for iterative software modification, and there is no Indian equivalent to a predetermined change control plan. The practice's approach was to define, within the dossier itself, a change classification taxonomy distinguishing changes requiring prior endorsement from those recordable within the quality system — and to have that taxonomy reviewed as part of the application rather than left to be litigated at the first retraining cycle.

3.5 Health Authority Interaction

CDSCO correspondence was more extensive than is typical for a Class C device, reflecting the reviewer's limited precedent for AI software in this indication.

The classification clarification returned Class C at month 5, consistent with the practice's recommendation.

The substantive review produced 31 observations across two rounds. Three themes dominated.

On performance evidence and population representativeness, the reviewer requested evidence that the algorithm's performance held in an Indian population. The manufacturer's pivotal dataset was predominantly North American and European, with a modest South Asian subgroup drawn from a UK screening programme. The reviewer's position was that a UK South Asian cohort was not an adequate proxy for an Indian screening population, citing differences in fundus pigmentation distribution, camera estate, image quality profile, and diabetic retinopathy prevalence and severity distribution. This was the single most consequential finding in the engagement.

On algorithm change control, the reviewer engaged the proposed taxonomy substantively and revised it. The reviewer's position was that any change to model weights constituted a change requiring prior intimation, irrespective of whether the manufacturer assessed the performance impact as negligible. The practice's proposed distinction between material and non-material weight changes was not accepted. Changes to the surrounding software — interface, integration, reporting — were accepted as recordable within the quality system.

On cloud deployment and data localisation, the reviewer queried where fundus images and inference outputs would be stored and processed. The manufacturer's architecture routed inference through US-hosted infrastructure. The reviewer did not assert a specific localisation requirement under MD Rules 2017 but noted the interaction with data protection obligations and requested a description of data flows and safeguards.

3.6 Pitfalls and Solutions

Pitfall: assuming EU or US classification transfers. In the absence of a software rule, Indian classification is an independent determination.

Solution. Pre-application classification clarification. The practice's standing advice for software entering India is to seek confirmation before filing, on the basis that four months spent at the front of a project is cheaper than a reclassification at month twelve, and that the classification determines fee, dossier structure, and licensing authority.

Pitfall: performance evidence not generalisable to the Indian screening population.

Solution. A retrospective validation study was executed using de-identified fundus images from three Indian sites — one public tertiary centre, one private hospital group, and one community screening programme — with grading by two independent Indian retinal specialists and adjudication of disagreement. Approximately 4,100 image sets were analysed. Performance was lower than in the pivotal dataset, with sensitivity for referable disease falling from 94.1% to 89.6%, driven principally by image quality in the community screening subset. Rather than suppress this, the submission presented it with an image quality gating threshold added to the software: images below a defined quality score return an ungradable output rather than a referral decision. CDSCO accepted the approach. The practice's assessment is that presenting a performance limitation with an engineered mitigation is consistently more successful than presenting aggregate performance that conceals it.

Pitfall: change control assumptions incompatible with the Indian framework.

Solution. The manufacturer's release cadence for the Indian market was decoupled from its global cadence. A defined Indian release train was established, batching model updates into scheduled endorsement submissions rather than propagating each global retraining cycle. This reduced endorsement frequency from four to one per year at the cost of the Indian deployment running behind the global version. The practice notes this is a product management decision as much as a regulatory one, and that software companies entering India should establish whether their architecture supports version divergence by market before committing to a registration timeline.

Pitfall: pre-registration pilot deployments. The manufacturer had characterised two hospital deployments as research collaborations. Screening outputs were reaching clinicians and influencing referral decisions.

Solution. The practice's assessment was that the deployments constituted use of an unregistered medical device rather than research. Deployments were suspended and restructured: one site was converted to a retrospective data contribution arrangement supporting the validation study with no live output, and the other was discontinued. The exposure was documented internally with a written rationale. The practice's position is that "research collaboration" is not a status that removes a device from regulatory scope where its output reaches clinical decision-making, and that this mischaracterisation is common among digital health companies entering emerging markets.

4. Case Study 3 — Japan: Novel Class D Catheter and the Subject Expert Committee Route

4.1 Client Profile

4.2 Project Scope and Duration

Scope covered classification, Investigational Medical Device determination, Subject Expert Committee submission and appearance, clinical investigation design and conduct in India, Form MD-14 prosecution, and post-approval commitments.

Duration: 41 months. The longest engagement in this set. Of that, the Indian clinical investigation accounted for approximately 22 months from protocol submission to database lock.

4.3 Product Characteristics

4.4 The Registration Process and Regulatory Strategy

The engagement was defined by the absence of an Indian predicate. Under MD Rules 2017, a device that is new to India in respect of its material, mechanism of action, or intended use falls to be treated as an Investigational Medical Device, and applications for such devices are referred to a Subject Expert Committee convened by CDSCO. The SEC is a panel of clinical and technical experts that reviews the application and makes a recommendation, including whether clinical investigation in India is required.

The manufacturer's initial position — supported by its Indian subsidiary — was that PMDA approval, FDA PMA, and EU MDR certification, together with a substantial multinational pivotal trial, ought to obviate Indian clinical investigation. The practice advised that this position was unlikely to succeed for a novel mechanism in a Class D coronary device, and that pursuing it would cost a full SEC cycle.

The strategy adopted was to concede the clinical investigation requirement in the initial submission and to shape it rather than resist it. Three elements followed.

Pre-submission SEC engagement. A meeting was sought before formal submission to establish the Committee's expectations regarding study design, sample size, and endpoint selection. This is not a formalised procedure comparable to an FDA Q-submission, and access is not guaranteed, but it was obtained.

Proposing the protocol rather than awaiting prescription. The submission included a full draft protocol for an Indian clinical investigation — a prospective, single-arm, multicentre study at six sites, n=120, with a primary endpoint of procedural success defined as residual stenosis below 50% without in-hospital major adverse cardiac events. Proposing a design permits negotiation from the manufacturer's starting position; awaiting SEC prescription does not.

Test licence for investigational supply. Import of devices for the clinical investigation required a separate test licence, applied for in parallel with the SEC submission rather than after SEC recommendation, on the assessment that the investigation would be required and that sequencing the test licence behind the SEC decision would add three months.

4.5 Health Authority Interaction

Subject Expert Committee interaction occurred across two appearances.

At the first appearance, at month 6, the Committee accepted the need for Indian clinical investigation and engaged the proposed protocol in detail. Three modifications were required. Sample size was increased from 120 to 150 on the Committee's assessment that the proposed size was insufficient to characterise safety in an Indian population. The site distribution was revised to require inclusion of at least two public-sector tertiary centres, the manufacturer having proposed six private centres; the Committee's stated rationale was representativeness of the Indian patient population. And a twelve-month follow-up endpoint was added to the proposed thirty-day primary endpoint.

The public-sector site requirement was the most operationally consequential modification and had not been anticipated.

At the second appearance, at month 34 following database lock, the Committee reviewed the Indian study results alongside the global dataset. The Committee's principal query concerned an imbalance in the Indian cohort: procedural success was comparable to the global dataset, but the Indian population presented with a higher proportion of diffuse calcification and smaller reference vessel diameters. The Committee requested subgroup analysis by vessel diameter and a labelling statement regarding vessel size.

CDSCO correspondence on the Form MD-14 application itself was comparatively light, the substantive assessment having occurred through the SEC. Observations concerned the generator's electrical safety documentation against applicable IEC standards, sterilisation validation, and labelling.

Post-approval commitments attached to the MD-15 included continued twelve-month follow-up reporting for the Indian cohort and periodic safety reporting under the Materiovigilance Programme of India.

4.6 Pitfalls and Solutions

Pitfall: expecting foreign approvals to waive Indian clinical investigation for a novel mechanism.

Solution. Conceding the requirement and shaping the study. The practice's assessment, consistent across engagements, is that local clinical investigation waiver is reliably obtainable for well-established device categories with documented predicate lineage and reliably unobtainable for novel mechanisms in high-risk indications. The determination should be made at project initiation because it drives timeline by roughly two years, and a manufacturer that budgets for eighteen months and encounters a forty-month path has a commercial problem rather than a regulatory one.

Pitfall: public-sector site requirement not anticipated. Private-sector site contracting was well understood by the Indian subsidiary; public tertiary centre engagement was not.

Solution. Two public centres were engaged through institutional ethics committee submission and administrative approval processes that ran materially slower than the private sites — approximately five months against six weeks. Enrolment at public sites also proceeded differently, with higher screening volumes and a different consent workflow. The practice's advice following this engagement is that manufacturers planning Indian clinical investigation should assume a public-site requirement for devices intended for broad populations and should build site contracting timelines accordingly.

Pitfall: Indian population characteristics differing from the global pivotal cohort.

Solution. The vessel diameter finding was addressed through subgroup analysis and an explicit labelling statement specifying the reference vessel diameter range in which the device had been evaluated in the Indian study. The practice's position is that presenting a population difference with a bounded labelling response is more effective before the SEC than presenting pooled data that obscures it, and that the Committee reads for population applicability specifically.

Pitfall: test licence sequencing.

Solution. Parallel application. This is a low-sophistication observation that nonetheless saved approximately three months: the test licence is a prerequisite for investigational supply, the SEC outcome for a novel Class D device is highly predictable, and waiting for formal confirmation of a predictable outcome is avoidable delay.

5. Case Study 4 — Germany: IVD Class C Tuberculosis Assay and the Importer Paradox

5.1 Client Profile

5.2 Project Scope and Duration

Scope covered assessment of the licence-holding exposure, Authorised Indian Representative restructuring, licence transfer negotiation and execution, menu extension for two additional assay targets, and public procurement qualification.

Duration: 26 months, of which licence transfer accounted for 15 months. The technical regulatory work was straightforward; the engagement was substantially contractual and negotiation-led.

5.3 Product Characteristics

5.4 The Registration Process and Regulatory Strategy

This engagement addressed the importer paradox — the structural consequence of a distributor holding the import licence. Under MD Rules 2017, the MD-15 import licence is issued to the importer, and the importer is the legal interface with CDSCO. Where that importer is the commercial distributor, the manufacturer's market authorisation sits inside its counterparty's corporate entity.

The manufacturer's exposure had crystallised commercially rather than regulatorily. The distributor, holding the MD-15 and named on product labelling, had proposed distribution terms the manufacturer assessed as materially below market. The manufacturer's assessment on obtaining advice was that its practical options were to accept the terms, or to obtain a new MD-15 under a different importer — which requires the manufacturer to work through a transfer process in which the incumbent's cooperation is, in practice, influential.

The strategy had three elements.

Establishing an independent Authorised Indian Representative. An independent regulatory entity was appointed as AIR, structurally separate from commercial distribution. This is the durable correction to the importer paradox and the practice's standing recommendation for any foreign manufacturer entering India.

Sequencing transfer against the menu extension. The manufacturer required two additional assay targets registered. Rather than pursuing these under the existing distributor-held licence, they were held back and filed under the new licence, which gave the manufacturer a commercial reason to establish the new licence independent of the transfer dispute, and reduced the incumbent's leverage by removing the manufacturer's dependence on the existing licence for its forward roadmap.

Public procurement qualification as parallel leverage. The assay's principal Indian volume opportunity was national tuberculosis programme procurement. Qualification for that channel required documentation the manufacturer controlled rather than the distributor. Advancing procurement qualification in parallel established a route to market that did not run through the incumbent.

5.5 Health Authority Interaction

CDSCO correspondence on the new licence application was routine. The dossier drew on the IVDR technical documentation and the existing Indian registration history, and the reviewer raised 14 observations, principally concerning the Authorised Indian Representative undertaking, labelling revision to reflect the new importer, and stability data under Zone IVB conditions for the cartridge reagents.

One observation was substantive. The reviewer queried the manufacturer's claimed limit of detection in the context of Indian specimen characteristics, requesting supporting data on performance with paucibacillary specimens. The manufacturer's IVDR performance evaluation addressed this but had not been presented in a form that isolated the paucibacillary subgroup.

Interaction regarding the transfer itself was procedural. CDSCO's position, as the practice understood it, was that the authority regulates licences rather than adjudicating commercial disputes between manufacturers and importers, and that a new licence application under a new importer would be assessed on its merits. This is a useful clarification and one manufacturers frequently misunderstand: the regulator is not a forum for resolving distributor conflict, but neither does it treat an incumbent's objection as dispositive.

Public procurement interaction with national programme bodies proceeded on a separate track and imposed requirements beyond the CDSCO registration, including price undertakings, supply volume commitments, and in-country service capability.

5.6 Pitfalls and Solutions

Pitfall: distributor-held MD-15. The originating exposure, and one created at market entry four years earlier by a decision taken for expedience.

Solution. Independent AIR appointment and a new licence under an independent importer, with distribution contracted separately. The practice's assessment is that the marginal cost of an independent AIR at market entry is a small fraction of the cost of remediating a distributor-held licence later, and that manufacturers consistently underweight this because the exposure is invisible while the commercial relationship is functioning.

Pitfall: forward roadmap dependent on the disputed licence.

Solution. Withholding the menu extension from the incumbent licence. This converted the new licence from a defensive necessity into a commercially motivated filing and materially altered the negotiation. The practice's general observation is that leverage in licence transfer disputes derives from having a route to market that does not require the counterparty's cooperation, and that establishing such a route is more productive than negotiating without one.

Pitfall: performance data not presented in the form the reviewer required.

Solution. The paucibacillary subgroup was extracted from the existing IVDR performance evaluation dataset and presented as a discrete analysis with a supplementary study on Indian sputum specimens. No new analytical validation was required; the deficiency was presentational. The practice notes that this pattern — adequate underlying data presented in a form that does not answer the reviewer's question — accounts for a substantial proportion of query rounds and is largely avoidable by reading the requirement set as a set of questions rather than a document checklist.

Pitfall: procurement requirements treated as a post-registration commercial matter.

Solution. Procurement qualification was advanced in parallel with registration rather than sequentially. For products whose principal Indian volume is public programme procurement, registration is a necessary but insufficient condition for market access, and the procurement track imposes requirements — service capability, supply commitments, pricing — with lead times comparable to the registration itself.

6. Case Study 5 — South Korea: Class C CT System and Multi-Authority Approval

6.1 Client Profile

6.2 Project Scope and Duration

Scope covered CDSCO registration, Atomic Energy Regulatory Board type approval, Bureau of Indian Standards and Legal Metrology assessment, wireless module clearance, and service infrastructure establishment as a registration-adjacent requirement.

Duration: 25 months to commercial installation readiness. CDSCO MD-15 issuance occurred at month 16; the remaining nine months were consumed by the non-CDSCO approvals and service establishment, which the manufacturer had not scheduled.

6.3 Product Characteristics

6.4 The Registration Process and Regulatory Strategy

The distinguishing feature of this engagement is that CDSCO registration was necessary but far from sufficient. A radiation-emitting imaging system with measuring functions and a wireless module engages at least four separate Indian approval regimes, administered by unrelated authorities on independent timelines.

CDSCO — Form MD-14 to Form MD-15 import licence as a notified Class C device.

Atomic Energy Regulatory Board — type approval for the radiation-generating equipment, and separately, site-level approvals for each installation covering room shielding layout and radiation safety officer designation. The type approval is a manufacturer-level obligation; the site approvals are recurring and installation-specific.

Bureau of Indian Standards and Legal Metrology — assessment of applicability to the system's measuring functions and display.

Wireless clearance — equipment type approval for the service diagnostics wireless module.

The strategic decision was to run these in parallel from month one rather than sequentially behind CDSCO. The manufacturer's initial plan had sequenced AERB behind MD-15 issuance on the reasoning that CDSCO registration was the primary approval. The practice's assessment was that AERB type approval had the longer lead time and no dependency on the CDSCO outcome, and that sequencing it second would extend the project by roughly eight months for no benefit.

A second strategic element concerned the AI reconstruction module. The practice advised presenting it within the system dossier as an integral component rather than as separable software, on the assessment that the module had no standalone intended purpose and that presenting it separately would invite an independent classification exercise of the kind described in Case Study 2, with attendant delay.

6.5 Health Authority Interaction

CDSCO correspondence produced 26 observations across two rounds. Substantive items concerned electrical safety and radiation safety documentation against applicable IEC standards including the CT-specific particular standard, dose reporting and display verification, and paediatric protocol documentation. The reviewer accepted the AI reconstruction module as an integral component and did not require separate classification, though it did request performance documentation demonstrating that reconstruction did not introduce clinically significant artefact.

AERB interaction was procedurally distinct and, in the practice's characterisation, more prescriptive. Type approval required submission of radiation output measurements conducted under specified conditions, leakage radiation data, and evidence of dose display accuracy. One finding required re-measurement: the manufacturer's leakage radiation data had been generated to a methodology accepted by MFDS and FDA that did not match AERB's specified measurement geometry. Re-measurement at an accredited facility added approximately four months.

AERB also raised the radiation safety officer requirement, which attaches to the installation site rather than the manufacturer, and which had implications for the manufacturer's commercial model: hospital customers require an RSO and shielding approval before the system can be commissioned, and installations at customers without existing CT capability face a lead time the manufacturer must manage as part of its delivery commitment.

Legal Metrology assessment concluded that the system's dose display fell within scope, requiring model approval and verification arrangements.

Wireless clearance was routine.

6.6 Pitfalls and Solutions

Pitfall: treating CDSCO as the only approval. The originating planning error.

Solution. Parallel multi-authority scheduling from month one, with a mapped dependency chart identifying which approvals gate commercial installation and which gate importation. The practice's standing advice is that manufacturers of radiation-emitting, measuring, or wireless-enabled devices should map the full Indian approval set before scheduling, and that CDSCO is frequently not the longest lead item.

Pitfall: test methodology mismatch. Leakage radiation data generated to a methodology AERB did not accept.

Solution. Re-measurement at an accredited Indian facility to AERB-specified geometry. The practice's general observation, applicable well beyond radiation testing, is that test data is only transferable between jurisdictions where the test methodology is common, and that manufacturers should verify methodology equivalence before assuming data reuse. Verifying this at project initiation costs a document review; discovering it at month twelve costs a test campaign.

Pitfall: site-level approval as a commercial delivery risk. The RSO and shielding approval requirements attach to the customer, not the manufacturer, but they determine whether the manufacturer can complete installation and recognise revenue.

Solution. A pre-installation site readiness assessment was built into the commercial process, with the manufacturer providing shielding layout support and RSO guidance to customers as a service element. This converted a delivery risk into a differentiator, at the cost of establishing an in-country capability the manufacturer had not planned. The practice notes that for capital equipment in India, site-level regulatory requirements should be modelled in the commercial process rather than treated as customer obligations, because the manufacturer bears the revenue consequence of customer non-readiness.

Pitfall: no service infrastructure. Not a regulatory requirement in itself, but a practical prerequisite for capital equipment and a factor in institutional procurement.

Solution. Service capability was established in three metropolitan regions before first installation, with a defined escalation path to Korea. This was scheduled into the 25-month timeline rather than pursued after registration. Institutional purchasers in India assess service capability in tender evaluation, and a registered product without service coverage is not commercially available in any meaningful sense.

7. Cross-Case Observations

7.1 Comparative Summary

7.2 Recurring Patterns

Dossier reuse requires gap analysis, not translation. Cases 1, 4, and 5 all involved query rounds arising from foreign dossiers presented without mapping to Indian requirement sets. The deficiencies were rarely substantive — Zone IVB stability, subgroup presentation, test methodology geometry — and were almost entirely avoidable by treating the Indian requirement set as an independent specification.

Local clinical data requirements are predictable from device novelty. Across the five cases, waiver was obtained where the device category was well established with documented predicate lineage, and refused where the mechanism was novel or the population characteristics materially different. This is a determination that can be made at project initiation with reasonable confidence, and it drives timeline by up to two years.

The licence holder decision compounds. Case 4's importer paradox originated in a market entry decision taken four years earlier. The general pattern — visible in the previous EU sample as well, in different statutory clothing — is that regulatory obligations frequently cannot be met without contractual rights secured before they are needed.

CDSCO is often not the binding constraint. In Cases 1, 3, and 5, the critical path ran through the NPPA ceiling economics, the Subject Expert Committee and clinical investigation, and AERB type approval respectively. Manufacturers who scoped their Indian projects as CDSCO registration projects consistently underestimated duration.

Presenting limitations with mitigations outperforms presenting aggregates. Case 2's image quality gating and Case 3's vessel diameter labelling both resolved authority concerns that pooled data would have obscured and that discovery would have escalated.

8. Conclusion

These five engagements share little at the technical level and a great deal at the structural level. In none of them was the binding difficulty of the device's safety, the quality of the underlying evidence, or the competence of the manufacturer's regulatory function. The difficulties were Indian machinery the manufacturer had not identified during planning — statutory price control, the absence of a software classification rule, the Subject Expert Committee route, the statutory position of the importer, the multi-authority approval set for radiation-emitting equipment — compounded, in three of the five cases, by commercial or contractual decisions taken years earlier for reasons unrelated to regulation.

The practical implication is consistent with the pattern observed in other jurisdictions: the highest-value regulatory work in an Indian market entry occurs before the dossier exists. Classification confirmation, local clinical data determination, price control exposure modelling, licence holder structuring, and mapping of the non-CDSCO approval set are all front-of-project activities, and all of them are substantially cheaper to resolve at month one than at month twelve. Engagements that front-loaded them completed within their planned envelopes. Engagements that began with dossier assembly did not.

Disclaimer

The information in this article is provided for general informational and educational purposes and does not constitute legal, regulatory, or professional advice. Manufacturer and partner practice identities are withheld under engagement confidentiality, and product descriptions have been generalised. The Medical Devices Rules, 2017 and associated CDSCO, NPPA, AERB, BIS, and Legal Metrology requirements are subject to amendment and to evolving administrative practice. Manufacturers should consult qualified regulatory affairs professionals and the relevant Indian authorities for device-specific guidance.